Shanghai Junshi Biosciences’ Tuoyi Files for 9th Indication in China for RCC Treatment
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180) has announced that the National Medical...
Junshi Biosciences
Shanghai Junshi Biosciences Gets FDA Approval for Phase III Study of Tifcemalimab in Small-Cell Lung Cancer
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877) has announced receiving approval from the US Food...
Shanghai Junshi Biosciences to List GDRs on Swiss Exchange, Raising RMB 3.4 Billion
China-based Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) is preparing to issue 68,292,200...
Coherus and Junshi Biosciences Await FDA Decision on Toripalimab After Inspection
US-based Coherus Biosciences Inc., (NASDAQ: CHRS) has disclosed that the US FDA has recently completed...
Harbour Biomed’s Porustobart Combo Shows Promise in HCC Treatment, ASCO Presentation Reveals
China-based Harbour Biomed (HKG: 2142) has announced the publication of results from a Phase Ib...
Shanghai Junshi Biosciences’ Tuoyi Combo for Triple Negative Breast Cancer Accepted for Review
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) has announced that the regulatory authorities...
US FDA Nears Regulatory Decision on Junshi Biosciences’ PD-1 Inhibitor Tuoyi
China-based Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) is approaching a significant regulatory milestone...
Shanghai Junshi Biosciences’ Tuoyi Shows Promise in Phase III Study for ES-SCLC
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) has announced encouraging results from the...
Shanghai Junshi Biosciences Inks Exclusive License Deal with Dr. Reddy’s Laboratories for Tuoyi
Shanghai Junshi Biosciences Co., Ltd (SHA: 688180), a China-based biotechnology firm, has announced an exclusive...
Junshi Biosciences’ RENOTORCH Study Meets Endpoints for RCC Treatment
Junshi Biosciences (HKG: 1877, SHA: 688180), a China-based biopharmaceutical company, has announced that its multi-center,...
Junshi Biosciences Submits Market Filings for PCSK9 mAb Ongericimab to NMPA
China’s Junshi Biosciences (HKG: 1877, SHA: 688180) has announced the submission of two market filings...
Junshi Biosciences’ Tuoyi Combo Shows Promise in Phase III Neotorch Study for NSCLC
China-based Junshi Biosciences (HKG: 1877, SHA: 688180) has published the results of the Phase III...
Harbour Biomed to Present Early Clinical Data for CTLA-4 Antibody Combo at AACR 2023
China-based Harbour Biomed (HKG: 2142) is set to release early clinical data for its CTLA-4...
Junshi Biosciences’ JS401 Receives NMPA Approval for Hyperlipidemia Clinical Trial
Junshi Biosciences (HKG: 1877, SHA: 688180), a leading China-based biopharmaceutical company, has announced that it...
Junshi Biosciences’ Senaparib Meets Primary Endpoint in Phase III Ovarian Cancer Study
China’s Junshi Biosciences (HKG: 1877, SHA: 688180) has declared that the Phase III FLAMES study...
Junshi Biosciences Challenges Alynlam’s PCSK9 siRNA Patent with CNIPA
Junshi Biosciences (SHA: 688180) is reportedly taking steps to challenge a key patent held by...
Junshi Biosciences and Rxilient Biotech Form JV to Commercialize Tuoyi in Southeast Asia
China-based biopharmaceutical company Junshi Biosciences (HKG: 1877, SHA: 688180) has announced a joint venture (JV)...
RemeGen’s RC48 Receives Two Clinical Trial Approvals for Breast Cancer Treatments
RemeGen Ltd (HKG: 9995) has announced the receipt of two clinical trial approvals for its...
Junshi Biosciences’ JS010 Receives NMPA Approval for Migraine Clinical Trials
China-based Junshi Biosciences (HKG: 1877, SHA: 688180) has announced that it has received clinical trial...
RemeGen Gains NMPA Approval for Phase I/IIa Study of RC88 with Junshi Bio’s PD-1 Inhibitor
China-based pharmaceutical firm RemeGen (HKG: 9995) has received approval from the National Medical Products Administration...